Term: VEGF Inhibitors
Definition: VEGF inhibitors are a class of drugs that block the activity of vascular endothelial growth factor (VEGF), a protein responsible for stimulating the growth of new blood vessels (angiogenesis), particularly in tumors.
Phonetic Pronunciation: (VEE-EH-jee-EF in-HIB-it-ers)
Etymological Origin: The term "VEGF" stands for "vascular endothelial growth factor," with "vascular" derived from the Latin "vasculum" meaning "small vessel," "endothelial" from the Greek "endon" meaning "within" and "thele" meaning "nipple" (referring to the thin layer of cells lining blood vessels), and "growth factor" indicating a substance that promotes cellular growth. "Inhibitor" comes from the Latin "inhibere," meaning "to hold back."
Significance in Asbestos Context: VEGF inhibitors are significant in the context of asbestos-related diseases, particularly mesothelioma. Mesothelioma tumors often rely on angiogenesis to grow and spread, and VEGF inhibitors can help slow tumor progression by cutting off their blood supply. These drugs are sometimes used as part of treatment regimens for patients with mesothelioma, offering a targeted approach to managing the disease.
Synonyms or Related Terms: Anti-angiogenic drugs, angiogenesis inhibitors, bevacizumab (a specific VEGF inhibitor).
Example Sentence: "VEGF inhibitors, such as bevacizumab, are being explored as a treatment option to slow the progression of mesothelioma caused by asbestos exposure."
Common Misconceptions:
